OpenBiome is dedicated to expanding safe access to fecal microbiota transplantation (FMT) and catalyzing research into the human microbiome.

 

We are a nonprofit stool bank and research platform.  We work collaboratively with clinicians, hospitals, and researchers to make FMT safe and affordable for patients suffering from recurrent C. difficile infection and to explore FMT's role in treating other diseases. Click below to read more about each part of our dual mission: 

  Nearly half a million Americans are infected with C. difficile each year. About 1 in 5 do not respond to antibiotics, but a treatment called Fecal Microbiota Transplantation (FMT) has been shown to be a promising new therapy. Read more about how OpenBiome is working to expand access to FMT for patients suffering from recurrent C. difficile infections. 

 

Nearly half a million Americans are infected with C. difficile each year. About 1 in 5 do not respond to antibiotics, but a treatment called Fecal Microbiota Transplantation (FMT) has been shown to be a promising new therapy.

Read more about how OpenBiome is working to expand access to FMT for patients suffering from recurrent C. difficile infections. 

  The human microbiome presents a new frontier in biomedical research, and current evidence suggests that the microbiome plays an influential role in not only C. difficile infection, but also in many aspects of human health and disease.  Read more about how OpenBiome is facilitating research efforts by developing a new set of tools and services.

 

The human microbiome presents a new frontier in biomedical research, and current evidence suggests that the microbiome plays an influential role in not only C. difficile infection, but also in many aspects of human health and disease. 

Read more about how OpenBiome is facilitating research efforts by developing a new set of tools and services.